Evidence map›Paper›PMID 28544821›Full record

ArticleCancer medicine2017

Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.

Kenji Fujiyoshi, Tatsuro Yamaguchi, Miho Kakuta, Akemi Takahashi, Yoshiko Arai, Mina Yamada, Gou Yamamoto, Sachiko Ohde, Misato Takao, Shin-Ichiro Horiguchi and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Kenji FujiyoshiDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-0310-5807
Tatsuro YamaguchiDepartment of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Miho KakutaDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Akemi TakahashiDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Yoshiko AraiDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Mina YamadaDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Gou YamamotoDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Sachiko OhdeCenter for Clinical Epidemiology, Graduate School of Public Health Planning Office, St. Luke's International University, OMURA Susumu & Mieko Memorial, St. Luke's Center for Clinical Academia, Tokyo, Japan.
Misato TakaoDepartment of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Shin-Ichiro HoriguchiDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Soichiro NatsumeDepartment of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Shinsuke KazamaDivision of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan.
Yusuke NishizawaDivision of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan.
Yoji NishimuraDivision of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan.
Yoshito AkagiDepartment of Surgery, Kurume University, Fukuoka, Japan.
Hirohiko SakamotoDivision of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan.
Kiwamu AkagiDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Saitama Cancer Center · JPTokyo Metropolitan Komagome Hospital · JPKurume University · JPSt. Luke's International University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsatellite instability (MSI) is an important biomarker for screening for Lynch syndrome, and also of response to immune checkpoint inhibitors. The aim of this study is to create a predictive model to determine which elderly patients with colorectal cancer (CRC) should undergo MSI and/or immunohistochemistry testing on the basis of clinicopathological data. We analyzed a test cohort of CRC patients aged ≥50 years (n = 2219) by multivariate logistic regression analyses to identify predictors of high-frequency MSI (MSI-H). The created prediction model was validated in an external cohort (n = 992). The frequency of MSI-H was 5.5% among CRC patients aged ≥ 50 years. The following five predictors of MSI-H were identified in the test cohort: female (1 point), mucinous component (2 points), tumor size ≥ 60 mm (2 points), location in proximal colon (3 points), and BRAF mutation (6 points). The area under curve (AUC) in the receiver-operating characteristic (ROC) analysis of this prediction model was 0.832 (95% confidence interval: 0.790-0.874). The sensitivity and specificity were 74.4% and 77.7%, respectively, for a cut-off score of 4 points. The receiver-operating characteristic curve of the validation cohort also showed an AUC of 0.856 (95% CI: 0.806-0.905). This prediction model is useful to select elderly CRC patients who should undergo MSI testing, and who may benefit from treatment with 5-FU-based adjuvant chemotherapy and cancer immunotherapy.

Indexed as

Microsatellite InstabilityModels, BiologicalAgedColorectal NeoplasmsDNA MethylationFemaleHumansMaleMiddle AgedMutationMutL Protein Homolog 1Promoter Regions, GeneticProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Reproducibility of ResultsTumor BurdenBRAF protein, humanKRAS protein, humanMLH1 protein, humanMutL Protein Homolog 1Proto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Colorectal cancerimmune checkpoint inhibitorLynch syndromemicrosatellite instabilitymismatch repair deficiencypredictive modeluniversal tumor screening

Identifiers

PMID28544821
PMCPMC5463087
OpenAlexW2617919506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.